Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT plus tislelizumab and bevacizumab for MSS/pMMR advanced colorectal cancer
ChiCTR2100053969Phase 4Recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab, bevacizumab and allogeneic fecal microbiota in colorectal cancer (CRC), sponsored by Yunnan Cancer Hospital. Primary endpoints: Changes of intestinal flora quantity and 15 immune functions. Started Jan 2022; status: recruiting.
02
Drugs
tislelizumabbevacizumaballogeneic fecal microbiota
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100053969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053969.